ABSTRACT 260

Abstract

Background and aims: Treatment of DKA requires hydration and frequent intravenous (IV) fluid modifications. No treatment studies have shown clinical benefit of rate of glucose or bicarbonate correction. Aims: We studied the use of Glucommander® a computer-based system to direct IV insulin infusion using blood glucose (BG) measurements. It utilizes a weight based algorithm to recommend insulin infusion rate and time to check next BG. New recommendations are offered hourly based on glucose measurements; the multiplier is adjusted depending on the patient’s proximity to target BG. Methods: After IRB approval a retrospective chart review was conducted on patients admitted to PICU from January 2009-December 2009. Inclusion criteria were defined as patient’s ages 1–18 years with diagnosis of DKA and/or type 1 diabetes. Patients were treated with the Glucommander®. Key outcome measures were analyzed (Table 1). Adverse events were recorded.Table: No title available.Results: 39/59 patients met inclusion criteria. Average age of patients was 11.82 ± 4.36 years (2–17). 38.46% had new diagnosis of Type 1 diabetes. There were 69.23% females and 30.77% males. Results: are stated in the Table 1. Conclusions: Use of Glucommander® is safe and effective for management of pediatric patients with DKA. There were no adverse events. Use of the Glucommander® achieves portability, user friendliness, staff satisfaction, and was less error prone.